Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy

References

• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol.19(2), 203–208 (2007).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol.6(10), 715–727 (2006).
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin. Immunopathol.26(1–2), 71–94 (2004).
   PubMed Web of Science ®Google Scholar
• Sprangers B, Fevery S, Van Wijmeersch B, De Somer L, Waer M, Billiau AD. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease? Front. Biosci.12, 4568–4594 (2007).
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant.41(5), 483–493 (2008).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408(6813), 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Takeshita F, Leifer CA, Gursel I et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol.167(7), 3555–3558 (2001).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta1489(1), 107–116 (1999).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin’s lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood105(2), 489–495 (2005).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Kamstrup S, Verthelyi D et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin. Immunopathol.22(1–2), 173–183 (2000).
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Rodeberg DA, Krieg AM,Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res.9(8), 3105–3114 (2003).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep.6(2), 88–95 (2004).
   PubMedGoogle Scholar
• Tam Y. Liposome encapsulation enhances the activity of immunostimulatory oligonucleotides. Future Lipidol.1(1), 35–46 (2006).
   Web of Science ®Google Scholar
• Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother.27(6), 460–471 (2004).
   PubMed Web of Science ®Google Scholar
• Moore DJ, Hwang J, McGreivy J et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Leichman G, Gravenor D, Woytowitz D et al. CpG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled Phase II study. Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3), 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner S, Weber J, Redman B et al. CPG 7909, a TLR9 agonist in metastatic melanoma: a randomized Phase II trial comparing two doses and in combination with DTIC. Presented at: 41st ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Weiner GJ. Immunostimulatory DNA sequences and cancer therapy. Springer Semin. Immunopathol.22(1–2), 107–116 (2000).
   PubMed Web of Science ®Google Scholar
• Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem.270(8), 1628–1644 (2003).
   PubMedGoogle Scholar
• Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta1489(1), 69–84 (1999).
   PubMed Web of Science ®Google Scholar
• Henry SP, Monteith D, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des.12(5), 395–408 (1997).
   PubMedGoogle Scholar
• Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr. Opin. Mol. Ther.2(3), 258–263 (2000).
   PubMedGoogle Scholar
• Kindrachuk J, Potter JE, Brownlie R et al. Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9. J. Biol. Chem.282(19), 13944–13953 (2007).
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer S, Kirschning CJ, Hacker H et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA98(16), 9237–9242 (2001).
   PubMed Web of Science ®Google Scholar
• Haas T, Metzger J, Schmitz F et al. The DNA sugar backbone 2´ deoxyribose determines Toll-like receptor 9 activation. Immunity28(3), 315–323 (2008).
   PubMed Web of Science ®Google Scholar
• Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol.5(2), 190–198 (2004).
   PubMed Web of Science ®Google Scholar
• Yasuda K, Rutz M, Schlatter B et al. CpG motif-independent activation of TLR9 upon endosomal translocation of “natural” phosphodiester DNA. Eur. J. Immunol.36(2), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet.28(1), 7–16 (1995).
   PubMed Web of Science ®Google Scholar
• Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol.45(5), 932–943 (1994).
   PubMed Web of Science ®Google Scholar
• Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev.3(1), 53–66 (1993).
   PubMedGoogle Scholar
• Yasuda K, Yu P, Kirschning CJ et al. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol.174(10), 6129–6136 (2005).
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science303(5665), 1818–1822 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol.24(10), 1211–1217 (2006).
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46(12 Pt 1), 6387–6392 (1986).
   PubMed Web of Science ®Google Scholar
• Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther.1(6), 923–947 (2001).
   PubMed Web of Science ®Google Scholar
• Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol.172(3), 1777–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Song S, Wang Y, Zhang Y et al. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG. Cancer Lett.256(1), 90–100 (2007).
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO, Hope MJ. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol.313, 322–341 (2000).
   PubMed Web of Science ®Google Scholar
• Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deliv. Rev.38(3), 291–315 (1999).
   PubMed Web of Science ®Google Scholar
• Maurer N, Wong KF, Stark H et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J.80(5), 2310–2326 (2001).
   PubMed Web of Science ®Google Scholar
• Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res.20(21), 5691–5698 (1992).
   PubMed Web of Science ®Google Scholar
• Meyer O, Kirpotin D, Hong K et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem.273(25), 15621–15627 (1998).
   PubMed Web of Science ®Google Scholar
• Mahato RI, Anwer K, Tagliaferri F et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum. Gene Ther.9(14), 2083–2099 (1998).
   PubMed Web of Science ®Google Scholar
• Tousignant JD, Gates AL, Ingram LA et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther.11(18), 2493–2513 (2000).
   PubMed Web of Science ®Google Scholar
• Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum. Gene Ther.12(6), 685–696 (2001).
   PubMed Web of Science ®Google Scholar
• Tan Y, Liu F, Li Z, Li S, Huang L. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Mol. Ther.3(5 Pt 1), 673–682 (2001).
   PubMed Web of Science ®Google Scholar
• Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res.17(5), 521–525 (2000).
   PubMed Web of Science ®Google Scholar
• Eliyahu H, Servel N, Domb AJ, Barenholz Y. Lipoplex-induced hemagglutination: potential involvement in intravenous gene delivery. Gene Ther.9(13), 850–858 (2002).
   PubMed Web of Science ®Google Scholar
• Barron LG, Meyer KB, Szoka FC Jr. Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum. Gene Ther.9(3), 315–323 (1998).
   PubMed Web of Science ®Google Scholar
• Wright MJ, Rosenthal E, Stewart L et al. β-galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: a cautionary tale. Gene Ther.5(3), 301–308 (1998).
   PubMed Web of Science ®Google Scholar
• Chiou HC, Tangco MV, Levine SM et al. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res.22(24), 5439–5446 (1994).
   PubMed Web of Science ®Google Scholar
• Dash PR, Read ML, Barrett LB, Wolfert MA, Seymour LW. Factors affecting blood clearance and in vivodistribution of polyelectrolyte complexes for gene delivery. Gene Ther.6(4), 643–650 (1999).
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr. Opin. Mol. Ther.3(2), 183–191 (2001).
   PubMedGoogle Scholar
• Faneca H, Simoes S, de Lima MC. Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim. Biophys. Acta1567(1–2), 23–33 (2002).
   PubMed Web of Science ®Google Scholar
• Bonte F, Juliano RL. Interactions of liposomes with serum proteins. Chem. Phys. Lipids40(2–4), 359–372 (1986).
   PubMed Web of Science ®Google Scholar
• de Jong S, Chikh G, Sekirov L et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother.56(8), 1251–1264 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson KD, Raney SG, Sekirov L et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int. Immunopharmacol.7(8), 1064–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol. Membr. Biol.15(1), 1–14 (1998).
   PubMed Web of Science ®Google Scholar
• Yu RZ, Geary RS, Leeds JM et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci.90(2), 182–193 (2001).
   PubMed Web of Science ®Google Scholar
• Wingender G, Garbi N, Schumak B et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol.36(1), 12–20 (2006).
   PubMed Web of Science ®Google Scholar
• Heckelsmiller K, Beck S, Rall K et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol.32(11), 3235–3245 (2002).
   PubMed Web of Science ®Google Scholar
• Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol.167(9), 5247–5253 (2001).
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta1510(1–2), 152–166 (2001).
   PubMed Web of Science ®Google Scholar
• Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun.197(2), 818–825 (1993).
   PubMed Web of Science ®Google Scholar
• Mui B, Raney SG, Semple SC, Hope MJ. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther.298(3), 1185–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother.50(10), 503–514 (2001).
   PubMed Web of Science ®Google Scholar
• Chesnoy S, Huang L. Structure and function of lipid-DNA complexes for gene delivery. Annu. Rev. Biophys. Biomol. Struct.29, 27–47 (2000).
   PubMedGoogle Scholar
• Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry32(3), 889–899 (1993).
   PubMed Web of Science ®Google Scholar
• Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol.167(6), 3324–3328 (2001).
   PubMed Web of Science ®Google Scholar
• Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J. Leukoc. Biol.77(1), 71–79 (2005).
   PubMed Web of Science ®Google Scholar
• Alving CR, Koulchin V, Glenn GM, Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev.145, 5–31 (1995).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods4(3), 210–216 (1994).
   PubMedGoogle Scholar
• Suzuki Y, Wakita D, Chamoto K et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res.64(23), 8754–8760 (2004).
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today8(20), 934–943 (2003).
   PubMed Web of Science ®Google Scholar
• Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med.8(8), 998–1007 (2006).
   PubMed Web of Science ®Google Scholar
• Raney SG, Sekirov L, DeJong SD, Brodsky II, Chikh G, Tam YK. Methylated CpG ODNs are potent adjuvants when encapsulated in stablized lipid particles. Presented at: 12th International Conference of Immunology and 4th Annual Conference of FOCIS. Montreal, Canada, 18–23 July 2004.
   Google Scholar
• Tam YK, deJong SD, Basha G, Wilson KD, Kazem M, Cullis P. Lipid encapsulation promotes co-localization of methylated CpG ODN and TLR9 in late endosomes: a new model for the immunostimulatory activity of CpG DNA. Presented at: 99th Annual AACR Meeting. San Diego, CA, USA, 12–16 April 2008.
   Google Scholar
• Lanuti M, Rudginsky S, Force SD et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res.60(11), 2955–2963 (2000).
   PubMed Web of Science ®Google Scholar
• Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol.171(8), 3941–3946 (2003).
   PubMed Web of Science ®Google Scholar
• Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res.9(7), 2693–2700 (2003).
   PubMed Web of Science ®Google Scholar
• Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Release97(1), 1–17 (2004).
   PubMed Web of Science ®Google Scholar
• Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol.163(3), 1552–1561 (1999).
   PubMed Web of Science ®Google Scholar
• Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther.6(11), 1867–1875 (1999).
   PubMed Web of Science ®Google Scholar
• Sakurai F, Terada T, Maruyama M et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther.10(9), 661–668 (2003).
   PubMed Web of Science ®Google Scholar
• Sturlan S, Schneeberger A, Fang M et al. Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response. Anticancer Res.23(6C), 4843–4851 (2003).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Kawakami K, Gursel I et al. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin. Cancer Res.9(17), 6516–6522 (2003).
   PubMed Web of Science ®Google Scholar
• Higgins RJ, McKisic M, Dickinson PJ et al. Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol. Immunother.53(4), 338–344 (2004).
   PubMed Web of Science ®Google Scholar
• Brignole C, Pastorino F, Marimpietri D et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl Cancer Inst.96(15), 1171–1180 (2004).
   PubMedGoogle Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90(6), 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol.157(5), 1840–1845 (1996).
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Link BK, Leonard J, Emmanouilides C, Albert G, Schmalbach T. Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL): a Phase I, open label dose-escalation study of safety and tolerability. Presented at: 40th ASCO Annual Meeting. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin. Oncol.30(4), 424–433 (2003).
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol.175(3), 1619–1627 (2005).
   PubMed Web of Science ®Google Scholar
• van Ojik HH, Bevaart L, Dahle CE et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res.63(17), 5595–5600 (2003).
   PubMed Web of Science ®Google Scholar
• Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin. Lymphoma1(1), 57–61 (2000).
   PubMedGoogle Scholar
• Leonard JP, Link BK, Emmanouilides C et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin’s lymphoma. Clin. Cancer Res.13(20), 6168–6174 (2007).
   PubMed Web of Science ®Google Scholar
• Moga E, Alvarez E, Canto E et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp. Hematol.36(1), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Sekirov L, Brodsky II, Raney SG, Chikh G, Tam YK. Intravenous administration of a liposomal CpG ODN (INX-0167) activates NK cells and potentiates ADCC. Presented at: 12th International Conference of Immunology and 4th Annual Conference of FOCIS. Montreal, Canada, 18–23 July 2004.
   Google Scholar
• Tam YK, Sekirov L, Raney S, Brodsky II, Chikh G. Liposomal encapsulation enhances the immunopotency of CpG ODN and potentiates ADCC by activation, expansion and enhanced homing of NK cells. Presented at: 97th Annual AACR Meeting. Washington, DC, USA, 1–5 April 2006.
   Google Scholar
• Vicari AP, Luu R, Zhang N et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol. Immunother.58(4), 615–628 (2009).
   PubMed Web of Science ®Google Scholar
• Joseph A, Louria-Hayon I, Plis-Finarov A et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine20(27–28), 3342–3354 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Imazu S, Gao JQ et al. Non-methylated CpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice. Biol. Pharm. Bull.29(1), 105–109 (2006).
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol.176(12), 7335–7345 (2006).
   PubMed Web of Science ®Google Scholar
• Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm.2(1), 22–28 (2005).
   PubMed Web of Science ®Google Scholar
• Wakita D, Chamoto K, Zhang Y et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int. Immunol.18(3), 425–434 (2006).
   PubMed Web of Science ®Google Scholar
• Lollini PL, De Giovanni C, Nicoletti G et al. Enhancement of experimental metastatic ability by tumor necrosis factor-α alone or in combination with interferon-γ. Clin. Exp. Metastasis8(2), 215–224 (1990).
   PubMed Web of Science ®Google Scholar
• Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine21(23), 3319–3329 (2003).
   PubMed Web of Science ®Google Scholar
• Jerome V, Graser A, Muller R, Kontermann RE, Konur A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. J. Immunother.29(3), 294–305 (2006).
   PubMed Web of Science ®Google Scholar
• Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol. J.1(2), 138–147 (2006).
   PubMedGoogle Scholar
• Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int. Arch. Allergy Immunol.142(3), 179–189 (2007).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J. Clin. Invest.117(5), 1184–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. The immunological adjuvant and vaccine carrier properties of liposomes. J. Drug Target.2(5), 351–356 (1994).
   PubMed Web of Science ®Google Scholar
• Chen WC, Huang L. Non-viral vector as vaccine carrier. Adv. Genet.54, 315–337 (2005).
   PubMed Web of Science ®Google Scholar